VIAN Therapeutics

1 known investors

VIAN Therapeutics develops a topical eye drop treatment for retinal diseases caused by angiogenesis and vascular permeability, offering a non-invasive alternative to intravitreal injections. The lead candidate targets age-related macular degeneration and diabetic macular edema by inhibiting pro-angiogenic factors and inflammatory cytokines.

BiotechHealthtechMedical Devices